Search

Your search keyword '"Blackford, Amanda L"' showing total 566 results

Search Constraints

Start Over You searched for: Author "Blackford, Amanda L" Remove constraint Author: "Blackford, Amanda L"
566 results on '"Blackford, Amanda L"'

Search Results

7. In proportion: approaches for displaying patient-reported outcome research study results as percentages responding to treatment

8. Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

9. Housing assistance among patients with cancer: SEER-Medicare US Department of Housing and Urban Development data linkage.

10. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.

14. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia

16. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation

20. Supplementary Data Tables S1-S5 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

21. Supplementary Data 2 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

22. Data from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

23. Supplementary Data 1 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

27. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

29. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience

30. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges

32. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

35. T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers

37. Data from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

40. Supplemental Figure 2 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

41. Supplementary table 8 from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

44. Supplemental Legend from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

45. Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

46. Supplemental Table 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

47. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

48. Supplementary Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

49. Supplemental Figure 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

Catalog

Books, media, physical & digital resources